ORKA 📈 Oruka Therapeutics - Overview
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Common Stock •
ORKA: Biologics, Psoriasis, Inflammatory, Skin, Diseases, Treatments
Oruka Therapeutics, Inc. operates as a biotechnology company. The Company develops novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis and other inflammatory diseases. Oruka Therapeutics serves patients in the United States.
Additional Sources for ORKA Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ORKA Stock Overview
| Market Cap in USD | 888m |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1997-08-08 |
ORKA Stock Ratings
| Growth 5y | -30.1% |
| Fundamental | - |
| Dividend | 56.0% |
| Rel. Strength Industry | 684 |
| Analysts | 4.86/5 |
| Fair Price Momentum | 36.74 USD |
| Fair Price DCF | - |
ORKA Dividends
| Dividend Yield 12m | 95.30% |
| Yield on Cost 5y | 50.31% |
| Annual Growth 5y | % |
| Payout Consistency | 100.0% |
ORKA Growth Ratios
| Growth Correlation 3m | -60.9% |
| Growth Correlation 12m | 73.9% |
| Growth Correlation 5y | -52.3% |
| CAGR 5y | -11.96% |
| CAGR/Mean DD 5y | -0.15 |
| Sharpe Ratio 12m | 0.94 |
| Alpha | 53.25 |
| Beta | 1.22 |
| Volatility | 85.39% |
| Current Volume | 2542.1k |
| Average Volume 20d | 387.6k |
What is the price of ORKA stocks?
As of December 22, 2024, the stock is trading at USD 20.31 with a total of 2,542,100 shares traded.
Over the past week, the price has changed by -7.43%, over one month by -8.51%, over three months by -18.76% and over the past year by +82.96%.
As of December 22, 2024, the stock is trading at USD 20.31 with a total of 2,542,100 shares traded.
Over the past week, the price has changed by -7.43%, over one month by -8.51%, over three months by -18.76% and over the past year by +82.96%.
Is Oruka Therapeutics a good stock to buy?
Probably not. Based on ValueRay Analyses, Oruka Therapeutics (NASDAQ:ORKA) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -30.07 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ORKA as of December 2024 is 36.74. This means that ORKA is currently undervalued and has a potential upside of +80.9% (Margin of Safety).
Probably not. Based on ValueRay Analyses, Oruka Therapeutics (NASDAQ:ORKA) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -30.07 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ORKA as of December 2024 is 36.74. This means that ORKA is currently undervalued and has a potential upside of +80.9% (Margin of Safety).
Is ORKA a buy, sell or hold?
Oruka Therapeutics has received a consensus analysts rating of 4.86. Therefor, it is recommend to buy ORKA.
Oruka Therapeutics has received a consensus analysts rating of 4.86. Therefor, it is recommend to buy ORKA.
- Strong Buy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for ORKA stock price target?
According to ValueRays Forecast Model, ORKA Oruka Therapeutics will be worth about 41.1 in December 2025. The stock is currently trading at 20.31. This means that the stock has a potential upside of +102.56%.
According to ValueRays Forecast Model, ORKA Oruka Therapeutics will be worth about 41.1 in December 2025. The stock is currently trading at 20.31. This means that the stock has a potential upside of +102.56%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 41.3 | 103.1% |
| Analysts Target Price | 41.3 | 103.1% |
| ValueRay Target Price | 41.1 | 102.6% |